Category: isoquinoline

Kurouchi, Hiroaki; Otani, Yuko; Ohwada, Tomohiko published an article in 2016, the title of the article was Facile synthesis of 5- to 7-membered benzolactam compounds via strongly facilitated electrophilic aromtic substitution reaction.Recommanded Product: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one And the article contains the following content:

Activation of aromatic ring-tethered carbamate compounds with trifluoromethanesulfonic acid to obtain benzolactams with 5- to 7-membered rings and examined the substrate scope and limitations of this activation method. In 5-membered ring formation, a halogen group on the aromatic ring did not greatly affect the reaction yield, but other electron-donating groups inhibited the cyclization reaction and various side-reactions occurred. In 7-membered ring formation, eletron-donating groups on aromatic ring promoted the cyclization reaction but cyclization of electron-deficient aromatic rings did not proceed well. The 6-membered ring formation reaction showed the greatest substrate generality. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Recommanded Product: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to aralkylcarbamoyloxy benzoate preparation triflic acid promoter electrophilic aromatic substitution, benzolactam preparation, Heterocyclic Compounds (One Hetero Atom): Higher-Membered Rings and other aspects.Recommanded Product: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 28, 2022, Gu, Qiong; Xu, Jun; Fang, Yuying published a patent.Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one The title of the patent was Process for preparation of benzimidazole compound and application thereof in preparation of ferroptosis inhibitor. And the patent contained the following:

The invention relates to preparation of a benzimidazole compound, and an application thereof in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in formula I or II. According to the benzimidazole compound provided by the present invention, a lipophilic group is introduced to an R1 position, and a specific group is introduced to an R2 position, such that the obtained compound has relatively good ferroptosis inhibitory activity and can be used as a lead compound for preventing and treating nervous system diseases such as stroke. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to benzimidazole compound preparation ferroptosis inhibitory, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Safety of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On February 28, 2021, Aseem, Sayed Obaidullah; Jalan-Sakrikar, Nidhi; Chi, Cheng; Navarro-Corcuera, Amaia; De Assuncao, Thiago M.; Hamdan, Feda H.; Chowdhury, Shiraj; Banales, Jesus M.; Johnsen, Steven A.; Shah, Vijay H.; Huebert, Robert C. published an article.Computed Properties of 1009104-85-1 The title of the article was Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis. And the article contained the following:

Transforming growth factor β (TGFβ) upregulates cholangiocyte-derived signals that activate myofibroblasts and promote fibrosis. Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) was used to investigate changes in chromatin accessibility. TGFβ stimulation caused widespread changes in histone 3 lysine 27 acetylation (H3K27ac), and was associated with global TGFβ-mediated transcription. In contrast, H3K9ac was gained in a smaller group of chromatin sites and was associated with fibrosis pathways. These pathways included overexpression of hepatic stellate cell (HSC) activators such as fibronectin 1 (FN1) and SERPINE1. The promoters of these genes showed H3K9ac enrichment following TGFβ. Of the acetyltransferases responsible for H3K9ac, cholangiocytes predominantly express Lysine Acetyltransferases 2A (KAT2A). Small interfering RNA knockdown of KAT2A or H3K9ac inhibition prevented the TGFβ-mediated increase in FN1 and SERPINE1. SMAD3 ChIP-seq and ATAC-seq suggested that TGFβ-mediated H3K9ac occurs through SMAD signaling, which was confirmed using colocalization and genetic knockdown studies. Pharmacol. inhibition or cholangiocyte-selective deletion of Kat2a was protective in mouse models of biliary fibrosis. Cholangiocyte expression of HSC-activating signals occurs through SMAD-dependent, KAT2A-mediated, H3K9ac, and can be targeted to prevent biliary fibrosis. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Computed Properties of 1009104-85-1

The Article related to biliary fibrosis cholangiocyte transforming growth factor histone h3 acetylation, epigenetics, fn, pai1, Mammalian Pathological Biochemistry: Digestive Tract Diseases and other aspects.Computed Properties of 1009104-85-1

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On April 9, 2004, D’Orchymont, Hugues; Van Hijfte, Luc; Zimmermann, Andre published a patent.Reference of 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of indazolecarboxamides as CDK1, CDK2, and CDK4 inhibitors for treating CDK-related diseases, in particular cancer. And the patent contained the following:

Title compounds I [R1 = H, halo, NH2, NHR2, NHCOR2, NO2, CN, CH2NH2, CH2NHR2, (un)substituted Ph, heteroaryl; Ar = (un)substituted Ph, heteroaryl; R2 = Ph, heteroaryl, (un)substituted alkyl (substituent = Ph or heteroaryl); n = 0, 1, 2, or 3; PG = protecting group selected from trimethylsilylethoxymethyl, mesitylenesulfonyl; their free bases, addition salts with acids, solvates and hydrates; with the exclusion of certain compounds] were prepared as cyclin-dependent kinase (CDK)-1, CDK2, and CDK4 inhibitors for treating cdk-related diseases, in particular cancer. For instance, reacting indazole-3-carboxylic acid with N-phenyl-1,4-phenylenediamine in the presence of DCC gave 58% II. I displayed IC50 values < 20 μM for the inhibition of CDK2, CDK1, and CDK4 in a test for measuring the enzymic activity of CDK2/Cyclin A, CDK1/Cyclin B, and CDK4/Cyclin D1, resp. I are useful for treating cancers, autoimmune diseases, inflammations, cardiovascular diseases, viral and fungal infections, hematol. diseases, and degenerative diseases of muscular system. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Reference of 4-Bromo-5-nitroisoquinoline

The Article related to indazolecarboxamide preparation cdk1 cdk2 cdk4 inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On October 7, 2021, Cheruvallath, Zacharia; Green, Jason; Johnson, Ben; Jones, Bejamin; Schleicher, Kristin; Sun, Huikai; Tang, Mingnam published a patent.Application In Synthesis of 5-Methylisoquinoline-1-carbonitrile The title of the patent was N-Heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists and their preparation. And the patent contained the following:

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. This disclosure also relates to materials and methods for preparing compounds of formula I, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4. Compounds of formula I wherein when X3 is NH and derivatives and O, X4 is a single bond, and X5 is N and CR5, and R1R2 are taken together to form (un)substituted benzene ring; when X3 is CR3c, X4 is N and CR4, and X5 is N and CR5, and R1R2 are taken together to form (un)substituted furan, (un)substituted pyrazole or (un)substituted benzene ring; L is O when A is CHR6; L is a bond when n is absent and CHR6; R3c and N are independently H, halo, OH, CN, (un)substituted C3-6 cycloalkyl, etc.; R6 is H; R5R6 can be taken together to form ethane-1,2-diyl bridge; R7 and R8 are independently H and (un)substituted C1-4 alkyl; R9 is H and (un)substituted C1-4 alkyl; R10 is azetidin-1-ylmethyl, pyrrolidin-1-ylmethyl and heterocyclyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)acetic acid with 2-(1,7-dimethyl-1H-indazol-3-yl)propan-2-amine followed by hydrolysis; the resulting 7-(2-(1,7-dimethyl-1H-indazol-3-yl)propan-2-yl)-2-(pyrrolidin-2- yl)acetamide underwent reductive methylation with formaldehyde to give compound II. The invention compounds were evaluated for their SSTR4 inhibitory activity. From the assay, it was determined that compound II exhibited pEC50 value of 8.2 and pIC50 value of 7.2. The experimental process involved the reaction of 5-Methylisoquinoline-1-carbonitrile(cas: 1367744-24-8).Application In Synthesis of 5-Methylisoquinoline-1-carbonitrile

The Article related to heteroarylalkyl heterocyclylacetamide preparation sstr4 agonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Application In Synthesis of 5-Methylisoquinoline-1-carbonitrile

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On August 2, 2012, Heller, Stefan; Ronaghi, Mohammad; Oshima, Kazuo published a patent.Application In Synthesis of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one The title of the patent was Methods for generating inner ear cells in vitro from pluripotent stem cells. And the patent contained the following:

Methods, compositions and kits are provided for generating inner ear cells in vitro. These methods find use a number of applications, such as in preparing inner ear cells for in vitro screening for agents that are toxic to inner ear cells, for in vitro screening for agents that prevent against, mitigate, or reverse the toxic effects of such agents, and for in vitro screening for agents that promote otoregeneration. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Application In Synthesis of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

The Article related to inner ear cell pluripotent stem in vitro, Fermentation and Bioindustrial Chemistry: Animal Cell Culture and other aspects.Application In Synthesis of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On December 31, 1993, Shanker, P. Sathya; Rao, G. S. R. Subba published an article.Recommanded Product: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one The title of the article was Synthesis of isoquinolines from indanones: total synthesis of illudinine. And the article contained the following:

Schmidt reaction of 5-methoxy or 7-methoxyindan-1-ones or their derivatives results exclusively in isocarbostyrils which are converted into 6-methoxy or 8-methoxyisoquinolines in good yields. This strategy has been extended to the total synthesis of illudinine Me ester (I) starting from hexahydroindacenecarboxylate II. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Recommanded Product: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to schmidt reaction methoxyindanone, amination ring expansion methoxyindanone, isoquinolinone tetrahydro, illudinine, Alkaloids: Alkaloids Containing One Nitrogen Atom In A Ring and other aspects.Recommanded Product: 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On April 1, 2004, Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles Goodman; Smith, Dana Rae; Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe, Chad Nolan published a patent.Reference of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one The title of the patent was Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions. And the patent contained the following:

Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3′ = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixtures thereof] were prepared as μ-, κ-, and δ-opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II suppressed opioid receptors at a dose of 0.3 μg/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical compositions are useful for the treatment, prevention, or amelioration of obesity and related diseases. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Reference of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

The Article related to aryloxy nicotinamide preparation opioid receptor antagonist antiobesity, aryl heteroaryl ether preparation opioid receptor antagonist antiobesity, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Reference of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 1, 2020, Yu, Xiyong; Lan, Huiyao; Hu, Wenhui; Yang, Zhongjin; Wu, Nannan published a patent.Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one The title of the patent was Azaindoles and their application as antitumor drugs. And the patent contained the following:

The invention provides azaindoles and its application, which can effectively inhibit the phosphorylation of SMAD3, and has good antitumor activity in the tumor model induced by LCC in rats. The invention provides azaindole or its pharmaceutically acceptable salt or stereoisomer or prodrug mol. as shown in formula I, wherein D is selected from C and N; and R2 does not exist when D is N; A and B are independently selected from N and CR3; R1 is selected from H, C1-C6 alkyl, C6-C10 aryl, C3-C8 cycloalkyl, halogen, CN; R2 selected from: H, C1-C6 alkyl; each R3 is independently selected from H, C1-C6 alkyl, halogen, CN; R4 is selected from carbonyl compounds; R5, R5a, R5b = H, halogen, CN, C1-C6 alkyl, C3-C8 cycloalkyl. For example, compound II was prepared in a multi-step synthesis. The title compound can be used as a pharmaceutical composition for the prevention and/or treatment of cancer. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

The Article related to azaindole anticancer agent elimination reaction amidation substitution, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On June 7, 2022, Tang, Feng; Li, Zhen; Zhang, Guobao; Zhou, Feng; Chen, Ping; Ren, Jinsheng published a patent.Product Details of 58142-46-4 The title of the patent was Preparation of (piperazinyl)tetrahydropyridopyrimidine derivatives and application for treating KRAS G12C mutant tumors. And the patent contained the following:

The present invention relates to the preparation of (piperazinyl)tetrahydropyridopyrimidine derivatives and uses thereof. In particular, (piperazinyl)tetrahydropyridopyrimidine derivatives I (R is -C(R6)=CH(R7), furanyl, -CH(F)(Cl), etc.; Q is selected from C=O or S(=O)2; R1 is selected from heterocyclyl or NR4R5; R2 is selected from aryl or heteroaryl; R3 is selected from hydrogen or NC-CH2; R4 and R5 are independently selected from hydrogen, alkyl, aryl or heteroaryl, alkylacyl, C1-4 alkyloxyacyl, or R4 and R5 together with the nitrogen atom to which they are attached form a heterocyclyl; R6 is selected from hydrogen or fluorine; R7 is selected from hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy, described C1-4 alkyl or C1-4 alkoxy is optionally by =O, halogen, C1-4 alkoxy, etc.; n is selected from 0, 1, 2; m is selected from 1, 2, 3) were prepared The inventive compounds or a pharmaceutically acceptable salts, pharmaceutical compositions are used in preparation of medicaments for preventing and/or treating KRAS G12C mutant tumors. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Product Details of 58142-46-4

The Article related to piperazinyl tetrahydropyridopyrimidine preparation antitumor agent, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem